Your search for prostate cancer matches 678 pages

Showing 201 - 250


prostate cancer

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).

prostate cancer

Howard I. Scher, MD, on the Prostate Cancer Working Group 3 Consensus

Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in castration-resistant prostate cancer (Abstract 5000).

prostate cancer

Howard M. Sandler, MD, Summarizes Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Howard M. Sandler, MD, of Cedars-Sinai Medical Center discusses the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

prostate cancer

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).

survivorship
supportive care
prostate cancer

Christopher J. Recklitis, PhD, MPH, on The Risk of Suicide After a Cancer Diagnosis

Christopher J. Recklitis, PhD, MPH, of the Dana-Farber Cancer Institute, discusses what is known about suicide after cancer, the risks faced by prostate cancer patients within the first year after diagnosis, and challenges across the treatment trajectory

prostate cancer

A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer

A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of men with advanced prostate cancer (Abstracts 2510, 2530).

head and neck cancer
prostate cancer

Bruce Minsky, MD, on Clinical Trial Results: The ASCENDE-RT Trial and a Multicenter Study on Prostate Cancer

Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).

prostate cancer

Anthony Zietman, MD, on Accelerating Treatment: RTOG 0415 Study on Prostate Cancer

Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

prostate cancer

Anthony Zietman, MD, on Hormonal Therapy and Salvage Radiation: Results of RTOG 9601

Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).

prostate cancer

Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).

prostate cancer

James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer

James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).

prostate cancer

Howard M. Sandler, MD, on Prostate Cancer: Results From RTOG 0415

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses this phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

prostate cancer

Christopher Brian Allard, MD, on Prostate Cancer Risk and Regular Aspirin Use

Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).

prostate cancer

Maha Hussain, MD, on Prostate Cancer: Keynote Lecture

Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.

prostate cancer

W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study

W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).

prostate cancer

Paul L. Nguyen, MD, on Prostate Cancer: Results of the NRG Oncology/RTOG 9601 Study

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiation therapy following radical prostatectomy and an elevated PSA (Abstract 3).

prostate cancer

Fred Saad, MD, on Prostate Cancer: The Year in Review (French Language Version)

Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.

prostate cancer

Fred Saad, MD, on Prostate Cancer: The Year in Review

Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.

prostate cancer

David P. Dearnaley, MD, on Prostate Cancer: Results from the CHHiP Trial

David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).

prostate cancer

A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance

A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).

prostate cancer

Even After Antiandrogen Therapy, Docetaxel Remains Useful in Prostate Cancer

A study presented at the 2016 Genitourinary Cancers Symposium showed that 40% of patients with metastatic castration-resistant prostate cancer treated with docetaxel following abiraterone (Zytiga) had at least a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this...

prostate cancer

DNA Damage and Repair Pathway Signature May Be Associated With Prognosis After Prostatectomy in High-Risk Prostate Cancer

In a study reported in JAMA Oncology, Evans et al identified a DNA damage and repair pathway gene signature that was significantly associated with outcomes after prostatectomy for high-risk prostate cancer independent of standard clinicopathologic factors. Study Details The study involved 1,090...

Prostate Cancer

Death Rates Significantly Reduced for Men Having Radical Prostatectomy vs Watchful Waiting

Estimated 15-year results from the Scandinavian Prostate Cancer Group Study (SPCG-4) show that men diagnosed with early prostate cancer and randomly assigned to radical prostatectomy continued to have significantly reduced rates of death from prostate cancer, death from any cause, and risk of...

Prostate Cancer

Sunitinib/Prednisone Improves Progression-free Survival but not Overall Survival in Metastatic Castrate-resistant Prostate Cancer

According to M. Dror Michaelson, MD, PhD, second-line therapy with sunitinib (Sutent) and prednisone improves progression-free survival but not overall survival in men with metastatic castrate-resistant prostate cancer previously treated with docetaxel-based chemotherapy. Dr. Michaelson, of the...

Prostate Cancer

Cabozantinib Shows Encouraging Activity in Metastatic Castrate‑resistant Prostate Cancer

Cabozantinib, a dual inhibitor of MET kinase and the vascular endothelial growth factor (VEGF) receptor, exhibits high, early single-agent activity in men with metastatic castrate-resistant prostate cancer, according to Maha Hussain, MD, FACP, who presented these findings at the 2011 ASCO Annual...

Prostate Cancer

Final Decision on Sipuleucel-T

The Centers for Medicare & Mediaid Services (CMS) issued a final decision to cover FDA-approved indications of sipuleucel-T (Provenge) in prostate cancer, calling the treatment “reasonable and necessary.” The CMS final decision assures provider reimbursement of sipuleucel-T for Medicare...

Prostate Cancer

Optimizing Treatment for Advanced Prostate Cancer Requires Shifting Focus from Individual Drugs to Integrated Therapies

Newer drugs, including sipuleucel-T (Provenge), cabazitaxel (Jevtana), and abiraterone (Zytiga), can extend survival modestly and ease symptoms for men with advanced prostate cancer. Maximizing the benefit to patients will require shifting the focus from developing individual drugs to developing...

Prostate Cancer

New Safety Information Reported for 5-alpha Reductase Inhibitors

The FDA announced that the Warnings and Precautions section of the labels for the 5-alpha reductase inhibitor class of drugs has been revised to include new safety information about the increased risk of being diagnosed with high-grade prostate cancer. This risk appears to be low, but health-care...

Prostate Cancer

Intermittent or Continuous Androgen Suppression Produces Comparable Survival after Radical Therapy in Prostate Cancer

Men with prostate cancer who receive intermittent courses of androgen-suppressing therapy can live as long as those who are treated with continuous therapy, according to results of a recently concluded study. Until now, standard treatment has consisted of continuous therapy, but this is expected to ...

Prostate Cancer

Androgen Deprivation Therapy plus Radiotherapy Increases Survival in Men with Localized Prostate Cancer

The addition of short-term androgen deprivation therapy to radiotherapy for men with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a prostate-specific antigen (PSA) level of 20 ng/mL or less “conferred a modest but significant increase in the 10-year rate of overall survival, from 57 to...

Prostate Cancer

At 5 Years, Brachytherapy Shows Quality-of-life Advantages over Radical Prostatectomy for Favorable-risk Prostate Cancer

Five years after treatment for favorable-risk prostate cancer, men who either chose or were randomly assigned to receive brachytherapy reported quality-of-life advantages in urinary and sexual domains and in patient satisfaction compared to men who received radical prostatectomy, according to a...

Prostate Cancer

Keeping a Positive Attitude

I’ve been in alcohol and drug recovery for 20 years, and my wife of nearly 50 years, Arlene, and I have been through a lot together during that time. So 2 years ago, when my doctor told us that I had stage III prostate cancer and a Gleason score of 8, we both looked at him and asked if we could...

Prostate Cancer

Androgen Deprivation plus Radiotherapy Increases Survival in Men with Localized Prostate Cancer

Adding short-term androgen-deprivation therapy to radiotherapy “conferred a modest but significant increase in the 10-year rate of overall survival, from 57% to 62%,” in men with localized prostate cancer enrolled in Radiation Therapy Oncology Group (RTOG) trial 94-08. “This increase was...

Prostate Cancer

Long-term Data Show Benefit of Degarelix Beyond 3 Years in Advanced Hormone-dependent Prostate Cancer

Degarelix (Firmagon) is effective and well tolerated beyond 3 years in patients with advanced prostate cancer, according to a recent study published in The Journal of Urology.1 The new study (CS21A) extends the conclusions of the pivotal phase III study (CS21) in which the risk of prostate-specific ...

Prostate Cancer

Radium-223 Chloride Gets Fast Track Designation

Bayer HealthCare Pharmaceuticals, Inc, announced that its investigational compound radium-223 chloride, which is exclusively licensed from Algeta ASA, has been granted Fast Track designation by the FDA for the treatment of castration-resistant (hormone-refractory) prostate cancer in patients with...

Prostate Cancer

Action Date Set for Denosumab Supplemental Application

Amgen announced that the FDA will target a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2012, for the supplemental Biologics License Application to expand the indication for denosumab (Xgeva) to treat men with castrate-resistant prostate cancer to reduce the risk of developing...

Prostate Cancer

Short-term Androgen Deprivation plus Radiotherapy Improves Outcomes in Intermediate-risk Prostate Cancer

The addition of short-term androgen-deprivation therapy to external-beam radiation therapy improved overall and disease-specific survival in men with nonbulky localized prostate cancer and prostate-specific antigen (PSA) levels up to 20 ng/mL, as reported recently in The New England Journal of...

Prostate Cancer

FDA Approves Denosumab to Increase Bone Mass in Patients with Cancer

Denosumab (Prolia) recently received FDA approval as a treatment to increase bone mass in patients at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.  Pivotal Trials The approvals were based...

Prostate Cancer

International Prostate Cancer Studies Report Inroads in Managing Bone Metastases

Treatment and prevention of bone metastases in patients with prostate cancer is coming of age, according to several studies presented at the European Multidisciplinary Cancer Congress (ECCO/ESMO/ESTRO). Among the most impressive studies reported was an international phase III trial of radium-223,...

Kidney Cancer
Prostate Cancer

Novel Management Strategies Assessed in Renal Cell and Prostate Cancers

At the Best of ASCO Miami meeting, William Oh, MD, of the Tisch Cancer Institute, Mount Sinai School of Medicine, New York, described new trends and remaining questions in the management of renal cell and prostate cancers. Axitinib vs Sorafenib in Second-line RCC Axitinib, a potent and selective...

Prostate Cancer

Physicians Can Help Patients Set Realistic Expectations for Sexual Functioning after Treatment for Prostate Cancer

Models that can be personalized to predict erectile function of individual patients following treatment for early-stage prostate cancer have been developed and validated in a study involving a total of 2,940 men, and are ready for use in clinical practice, according to Martin G. Sanda, MD, the...

Prostate Cancer

Hypofractionated Radiotherapy Effectively Controls High-risk Prostate Cancer

The use of hypofractionated intensity-modulated radiotherapy (IMRT) appears to be a reasonable option for men with intermediate- to high-risk prostate cancer,1 reported Alan Pollack, MD, Chairman of Radiation Oncology at the University of Miami Miller School of Medicine in Miami and lead...

Prostate Cancer

Fewer Rectal Side Effects with IMRT than with 3D-CRT for Prostate Cancer

The use of intensity-modulated radiation therapy (IMRT) is associated with fewer acute and late toxic effects than is three-dimensional conformal radiation therapy (3D-CRT) in men with localized prostate cancer, according to preliminary analysis of the Radiation Therapy Oncology Group (RTOG) 0126...

Prostate Cancer

Prostate Cancer Screening Reconsidered

Prostate cancer is the most prevalent nonskin cancer in men. An estimated 16% of men are diagnosed with prostate cancer, yet only 3% of men die from it.1 Unlike other cancers, prostate cancer is associated with a prolonged lead-time, meaning it can take anywhere from 5 to 12 years to become...

Breast Cancer
Prostate Cancer

What You Should Know about Denosumab (Prolia) for Increasing Bone Mass during Breast and Prostate Cancer Therapies

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indications In September 2011, the monoclonal antibody RANKL...

Prostate Cancer

Sipuleucel-T Should Be Used Early in Metastatic Castrate-resistant Prostate Cancer, before Chemotherapy

When sipuleucel-T (Provenge) was approved by FDA in April 2010, it was the first vaccine to be approved as a treatment for prostate cancer and was hailed as a major advance. Although sipuleucel-T is now reimbursable by Medicare, some physicians are not clear about when to use it, and patients who...

Prostate Cancer

Data on Watchful Waiting for Low-risk Prostate Cancer May Swing Focus to Higher-risk Tumors and Quality of Life

Surgery did not increase survival rates compared to watchful waiting in men with clinically localized prostate cancer. Results were particularly strong for men with prostate-specific antigen (PSA) levels of 10 ng/dL and under, and those who have low-risk disease, according to data from the Prostate ...

Prostate Cancer

NIH Panel Endorses Active Surveillance in Low-risk Prostate Cancer

Active surveillance of localized prostate cancer is a viable management option that should be offered to low-risk patients in place of immediate treatment, said a panel of experts convened by the National Institutes of Health. A fairly new concept, active surveillance takes a more proactive...

Prostate Cancer

Risk of Sexual and Continence Problems No Lower with Robotic than with Open Surgery

Although robotic-assisted laparoscopic radical prostatectomy “is eclipsing open radical prostatectomy among men with clinically localized prostate cancer,” the risks of problems with sexual functioning and continence are no lower with robotic than open surgery, according to a study in the Journal...

Prostate Cancer

Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication Abiraterone acetate (Zytiga) (an oral agent that...

Advertisement

Advertisement



Advertisement